Used in targeted cancer therapy, particularly for tumors overexpressing EGFR such as non-small cell lung cancer, colorectal cancer, and head and neck cancers. Binds specifically to the extracellular domain of EGFR, blocking ligand binding and downstream signaling pathways involved in cell proliferation and survival. Employed as a reference in biosimilar development and quality control due to its well-characterized binding and functional profile. Also utilized in preclinical research to validate EGFR-targeting agents and assess receptor expression in tumor models.